Unnamed: 0,patient_filename,t,text,type,n,cmem_t_reasoning,cmem_t_ans_str,cmem_t_num_update
1490,TCGA-OL-A97C.1582865E-9294-4D78-8B16-92FB70381D15,2,"FINAL PATHOLOGIC DIAGNOSIS. A. Sentinel lymph node #1, left, biopsy: -One reactive lymph node, negative for tumor (0/1). B. Sentinel lymph node #2, left, biopsy: -One reactive lymph node, negative for tumor (0/1). C. Left axillary lymph node #3, biopsy: -Two reactive lymph nodes, negative for tumor (0/2). D. Left axillary lymph node #4, biopsy: -One reactive lymph node, negative for tumor (0/1). E. Left axillary non-sentinel lymph node, biopsy: -One reactive lymph node, negative for tumor (0/1). F. Left breast, mastectomy: -Malignant phyllodes tumor (25 x 17 X 16.5 cm) with heterologous. (chondrosarcomatous, fibrosarcomatous-like, and. fibro-myxosarcomatous-like differentiation). - Margins of resection are free of phyllodes tumor (0.5 mm from posterior. margin, > 6 mm from closest anterior inferior aspect). - The tumor abuts the dermis of the nipple areolar complex. - Nipple without diagnostic abnormality. - Focus of atypical ductal hyperplasia, see comment. - Intraductal hyperplasia, usual type. - Benign skin. G. Pectoralis major muscle, new outer margin, excision: -Fibroadipose tissue and skeletal muscle with degenerative changes,. negative for tumor. Clinical History: The patient is a. -year-old female with breast cancer undergoing simple. mastectomy, breast reconstruction, and sentinel node biopsy. Comment. F. CK5/14 supports a small focus of atypical ductal hyperplasia. All IHC. controls were appropriate. Specimens Received: A:F/s 1st sentinel node left breast. B: F/s 2nd sentinel node left breast. C: Left axillary lymph node #3. D: Left axillary lymplh node #4. E: Left axillary non-sentinel lymph node. F: Left breast. G: Pectoralid(sp) major muscle. E. The fifth container is additionally identified as, 'left axillary. non-sentinel lymph node'. Received fresh and placed in formalin is a 0.7 X 0.6. X 0.4 CM lymph node that is bisected and submitted in E1. F. The sixth container is additionally identified as, 'left breast. Long. stitch-lateral margin. Short stitch-superior margin. Please weigh the specimen. per Dr. Received fresh and placed in formalin is a 4,580 gm. mastectomy specimen measuring 25 cm from medial to lateral, 20 cm from superior. to inferior and 16.5 cm from anterior to posterior. There is a 25 x 20 cm. wrinkled skin ellipsecovering the entire anterior surface, with a short suture. designating the superior pole and a long suture designating the lateral pole. The areola measures 5.5 CM in diameter and the nipple measures 1.5 X 1.2 x 0.3. CM. The nipple-areolar complex displays no evidence of ulceration or retraction. The deep surface is inked black and the specimen is sectioned from medial to. lateral into 12 slices (nipple at slice 6-7) to reveal a 25 x 17 x 16.5 CM mass. with a variegated cut surface characterized by tan, fleshy regions intermixed. with dusky, gray-green regions and golden-yellow adipose, with scattered coarse. granularity and hemorrhage. The superior portions of slices 2-10 contain a. cystic space filled with hemorrhagic to slightly mucinous fluid. The mass. grossly extends to the posterior margin (slice 9) and is located 0.2 CM from the. green ink. Multiple sections of the mass, skin, and margins are submitted as. follows: Gross Description: The specimens are received in seven containers each labeled with the patient's. name and medical record number. A. The first container is additionally identified as, 'F/S first sentinel node. left breast : Received fresh for frozen section diagnosis is a 2 X 1.2 X 0.8 CM. lymph node that is entirely frozen and called, 'one benign lymph node,' by Dr. The frozen section remnants are submitted in A1-A2 FS. B. The second container is additionally identified as, 'F/S second sentinel. node left breast'. Received fresh for frozen section diagnosis is a 2.0 X 1.2 x. 0.6 CM lymph node that is entirely frozen and called, 'one benign lymph node,'. by Dr. The frozen section remnants are submitted in B1FS. C. The third container is additionally identified as, 'Left axillary lymph node. #3. Count. Received fresh for frozen section diagnosis are 2 lymph nodes. measuring 0.6 and 1.2 CM in greatest dimension. They are entirely frozen and. called, '2 benign lymph nodes,' by Dr. The frozen section remnants are. submitted in C1-C2 FS. D. The fourth container is additionally identified as, 'Left axillary lymph. node #4. Count- : Received fresh for frozen section diagnosis is a 1.3 CM. lymph node that is entirely frozen and called, 'one benign lymph node,' by Dr. , The frozen section remnants are submitted in D1FS. F1-F2: Slice 11. F3-F4: Slice 10. F5-F6: Slice 9, closest approach to black ink. F7-F8: Slice 8. F9: Slice 7. F10-F11: Slice 6 (nipple). F12: Slice 5. F13: Slice 4, closest approach to green ink. F14-F15: Slice 3. F16-F17: Slice 2. F18: Slice 1. Tissue fixed for at least 6 hours in 10% NBF and no more than 72 hours. G. The seventh container is additionally identified as, 'pectoralis major. muscle new outer margin lateral long black, new superior margin black'. Received. fresh and placed in formalin is a 24.3 g, 7 X 4.5 x 2.2 CM portion of irregular,. ragged, partially disrupted fibroadipose and muscle tissue designated with a. long suture marking new outer margin lateral, and a black suture designating new. superior margin. A gross photograph is taken. The specimen is inked as follows: New outer lateral margin-orange. Superior-blue. Inner-black. Anterior-yellow. Posterior-red. The specimen is serially sectioned from superior to inferior into 13 slices to. reveal scattered palpable nodules. Sections are submitted as follows: G1: Superior tip (slice 1), shaved. G2: Slice 3. G3-G4: Slice 5. G5-G6: Slice 7. G7-G8: Slice 9. G9: Slice 11. G10: Slice 13. Intraoperative Consult Diagnosis: A1-A2 FS: 'one benign lymph node,' by. 81 FS: 'One benign lymph node,' by. C1-C2 FS: '2 benign lymph nodes,' by. D1 FS: 'One benign lymph node,' by.",BRCA,0,"The T stage for breast cancer is determined by the size of the tumor. In this report, the tumor size is described as 'a 25 x 17 x 16.5 CM mass' in the left breast. According to the AJCC staging system, T1 tumors are 2 cm or less in size, T2 tumors are more than 2 cm but not more than 5 cm in size, T3 tumors are more than 5 cm in size, and T4 tumors involve the chest wall or skin. Therefore, the tumor in this report is a T2 tumor.",T2,0.0
868,TCGA-AR-A1AY.01D97550-C616-4001-85A5-5502D35FA38E,0,"Final Diagnosis. Breast, left, wide local excision: Infiltrating ductal carcinoma, Nottingham grade III (of III),. [tubules 3/3, nuclei 3/3, mitoses 2/3; Nottingham score 8/9], forming a 2.0 x 1.8 x 1.5 cm. circumscribed mass with central fibrosis [AJCC pTic]. Focal (5%) high grade ductal carcinoma. in situ with necrosis is present outside the main tumor mass. Angiolymphatic invasion is absent. The non-neoplastic breast parenchyma shows nonproliferative fibrocystic changes. Calcifications. are present in malignant ducts. Biopsy site changes are present. All surgical resection margins,. after a single separately submitted re-excision of the anterior/inferior margin, are negative for. tumor (minimum tumor free margin, 0.7 cm, superior margin). Lymph nodes; left axillary sentinel Nos. 1, 2, and 3; sentinel biopsies: A single (of 3) left. axillary sentinel lymph node (SLN No. 1) is positive for isolated tumor cell cluster [AJCC pNO. (i+) (sn)]. This isolated tumor cell cluster measures 0.11 mm and is seen on cytokeratin and H&E. staining. Blue dye is identified in all three sentinel lymph nodes. Immunohistochemical. cytokeratin stain was performed on the paraffin embedded sentinel lymph node tissues and. confirm the H&E impression. Lymph node, left axillary, excision: A single nonsentinel lymph node is negative for metastatic. carcinoma.",BRCA,0,"The report states that the size of the tumor is 2.0 x 1.8 x 1.5 cm, which falls within the T1 category of tumors that are 2 cm or less in size.",T1,1.0
605,TCGA-A7-A6VV.C26EAF0E-202B-4F3E-9E59-3395A1BFCAB8,1,"Final Surgical Pathology Report. Procedure: Diagnosis. A. Sentinel lymph node, right axilla, biopsy: One negative lymph. node (0/1). Breast, right, mastectomy: Invasive ductal carcinoma, grade 3,. size 4.5 cm in greatest dimension, with ductal carcinoma in-situ,. grade 3 with necrosis; negative margins of excision. C. Breast, left, mastectomy: Focal atypical ductal hyperplasia;. negative margins of excision. D. Lymph nodes, right axilla, regional resection: Four negative. lymph nodes (0/4). Microscopic Description: Invasive carcinoma: Histologic type: Ductal. Histologic grade: 3. Overall grade: 9/9. Architectural score: 3. Nuclear score: 3. Mitotic score: 3. Greatest dimension (pT) : Size 4.5 cm in greatest dimension. Specimen margins: Negative. Vessel invasion: Not identified. Nipple (Paget's : Negative. Invasion of skin or chest wall: Negative. Ductal carcinoma in situ: Histologic pattern: Solid, cribriform. Nuclear grade: 3. Central necrosis: Present. DCIS of total tumor (if mixed) : 10%. Extensive intraductal component (present/absent) : Absent. Specimen margins: Negative. Calcification: Present. Description of non-tumorous breast: Fibrocystic changes including. apocrine metaplasia with cyst formation. Comments: Prior biopsy site identified. Focal atypical ductal. hyperplasia, with partial involvement of a duct by a cribriform cell. population, is present within the left breast. Distant metastasis (pM) : Unknown. Lymph nodes: Number of positive nodes of total: 0 of. 5. Size of largest metastasis: N/A. Extracapsular extension (present/absent} : N/A. pN: pNO. Prognostic markers: See previous core biopsy at. Specimen. A. Right sentinel node (axillary). B. Right breast tumor at 12:00. C. Left breast tissue. D. Right axillary content. Clinical Information. Right breast, tumor at 12:00, large mass + for carcinoma right breast. Intraoperative Consultation. A. nno regative lymph node. Gross Description. A. Received unfixed for frozen section, labeled sentinel node right, is. a lymph node that is fat-replaced and 2 x 1.5 x 1.5 cm, entirely frozen. in 3 blocks. B. Received unfixed for tissue procurement, labeled right breast, is a. 1444 gram right breast that is unoriented and 23 cm medial to lateral,. 22 cm superior to inferior, and 4.5 cm anterior to posterior. There. is. an anterior black skin ellipse, 20 x 5 cm with 5 cm areola and 1.5 cm. nipple. There is a tan-gritty tumor at 12:00, up to 4.5 cm in greatest. dimension, and close to the anterior margin. Sections as follows: 1-6. continuous tumor, 7/8 tumor, 9 tumor, 10 RUQ random, 11 RLQ random, 12. LLQ random, 13 LUQ random, 14 nipple, 15 areola. C. Received unfixed, labeled left breast, is a portion of fibroadipose. breast tissue and skin that is 818 grams and 26 x 17 X 5 cm. Skin. is. darkly pigmented, and without focal lesions. Sectioning through the. breast tissue shows no mass lesions. Representative sections in. 8. blocks. D. Received unfixed, labeled right axillary content, is a 9 x 7 x 2 cm. portion of fatty nodal tissue. Lymph nodes are identified: 1 one. node, 2 two nodes, 3 one node.",BRCA,0,"The T stage is determined by the size of the tumor. T1 tumors are 2 cm or less in size, T2 tumors are more than 2 cm but not more than 5 cm in size, T3 tumors are more than 5 cm in size, and T4 tumors involve the chest wall or skin. The report states that the tumor size is 4.5 cm in greatest dimension. Therefore, the T stage is T3.",T3,1.0
940,TCGA-B6-A0WX.EE5BB205-D59B-4FEF-8D8F-D5720EDEB075,2,"Pat. Surgical Pathoro. 1. CLINICAL HISTORY : Left breast mass. Locally advanced left breast Ca. GROSS EXAMINATION: A. ""Breast biopsy"" received and fixed. The specimen consists of a 3.1 x 2.4 x. 1.3 cm unoriented fragment of yellow-tan soft fibroadipose tissue which is. inked blue and sectioned to reveal a 1.5 x 1.0 x 1.0 cm firm white-tan ill-. defined lesion that extends to the inked surgical margin. The remainder of. the tissue consists of adipose tissue. The specimen is entirely submitted as. Block A1-A10. for Dr. ;lides to Dr. DIAGNOSIS: A. ""LEFT BREAST"" (INCISIONAL BIOPSY) : INVASIVE PLEOMORPHIC LOBULAR CARCINOMA. N.S.A.B.P. NUCLEAR GRADE 2 OF 3. N.S.A.B.P. HISTOLOGIC GRADE 3 OF 3. LYMPHATIC/VASCULAR INVASION: ABSENT. IN-SITU CARCINOMA: ABSENT. STATUS OF NON-NEOPLASTIC BREAST TISSUE: NOT APPLICABLE (INCISIONAL. BIOPSY) . SIZE OF BIOPSY: 3.1 x 2.4 X 1.3 CM. (DIFFUSELY INVOLVED BY INVASIVE. CARCINOMA). MICROCALCIFICATIONS: ABSENT. SURGICAL MARGIN STATUS: NOT APPLICABLE (INCISIONAL BIOPSY). ESTROGEN/PROGESTERONE RECEPTOR AND CELL CYCLE ANALYSIS: PENDING. METHODOLOGY: IMMUNOHISTOCHEMISTRY, PARAFFIN BLOCK (A5). I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es) . M.D. ADDENDUM 1: Tissue was sent to the. for assay of the estrogen. and. progesterone receptors. The estrogen receptor activity was judged to be. negative with an estimated FMOL value of 0. The progesterone receptor activity. was judged as negative with an estimated FMOL value of 0. Please refer to. for a complete report. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es) . M.D. Page #. ADDENDUM 2: Immunostaining for HER2/neu (c-erbB-2) oncoprotein is performed on recut. sections of block A5. The immunostaining is done using DAKO rabbit anti-human. c-erbB-2 oncoprotein which is an affinity-isolated antibody. product. number. ) The immunostaining is performed after antigen retrieval by. heating the unstained sections at 95 degrees centigrade for 20 minutes in 10. mM citrate buffer, pH 6.0. The primary antibody is used at a dilution of. 1:3000 (manual staining), with an incubation for one hour at 37 degrees. centigrade. The Histostain Plus kit (. is used as the. detection system. Rare tumor cells exhibit barely perceptible, complete. membrane staining, but their number is too few to indicate overexpression of. HER2/neu oncoprotein. The majority of tumor tumor cells have barely. perceptible, focal membrane staining (score = 1+), indicating that the tumor. does NOT overexpress HER2/neu oncoprotein. I certify that I personally conducted the diagnostic evaluation of the above. specimen (s) and have rendered the above diagnosis (es) . M.D., , Ph.D. Pager t. 2 of 2.",BRCA,1,"The size of the tumor is 1.5 cm (lesion size 1.5 x 1.0 x 1.0 cm), which falls within the T2 category of 'more than 2 cm but not more than 5 cm in size'.",T2,1.0
1317,TCGA-E9-A24A.392524F7-B570-4047-A439-71FC15642DC8,0,OC#: Laterality:Right upper outer quadrant. Path Report: BREAST TISSUE CHECKLIST. Specimen type: Lumpectomy. Specimen size: Not specified. Tumor site: Upper outer quadrant. Tumor size: 1.4 X 0 x 1.8 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 1/10 positive for metastasis (Axillary 1/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None.,BRCA,1,"The report states that the tumor size is 1.4 x 0 x 1.8 cm. According to the rules provided, T1 tumors are 2 cm or less in size. Since this tumor is smaller than 2 cm, it falls under the T1 category.",T1,2.0
765,TCGA-AN-A0FX.0CC079D3-EB90-47B5-B554-599A67C9E12A,1,Sex: Female. Diagnosis: Breast Cancer Histological description: metaplastic carcinoma. Anatomic Site: Left Breast Tumor location: Primary. Tissue Specification: Tumor Specimen Matrix: Tissue Specimen Format: Frozen. Container: cryomold Type of Procurement: Radical mastectomy Grade: 3. T Stage: 2 N Stage: 0 M Stage: 0 Treatment: none. Treatment Details: n/a. Normal Sample. Anatomic Site: Blood Sample Type: Normal Type of Procurement: blood draw. Matrix: Blood Specimen Format: frozen Container: tube.,BRCA,0,"The report indicates a T Stage of 2, which means the tumor is more than 2 cm but not more than 5 cm in size. This is based on the rule 'T2 tumors are more than 2 cm but not more than 5 cm in size.'",T2,3.0
1291,TCGA-E9-A1R7.FA19C3C4-E13B-464B-84CC-3AF7E83D5B9C,1,"DC ID: Gross Description: Lump with the tumor of 2.5 x 2.3 cm in size;. lymph nodes are soft, hyperemic, up to 1 cm in their largest dimension. Microscopic Description: Infiltrating duct carcinoma ; G2. Ten dissected lymph nodes demonstrate reactive changes. Diagnosis Details: Tumor Features: Unknown, Tumor Extent: T2 tumor size more than 2cm not more than 5 cm, Venous Invasion: Absent,. Margins: Absent, Treatment Effect: Comments: BREAST TISSUE CHECKLIST. Specimen type: Lumpectomy. Specimen size: Not specified. Tumor site: Upper outer quadrant. Tumor size: 2.3 x 0x 2.5 cm. Grossly evident lesion: Yes. Histologic type: Infiltrating ductal carcinoma. Histologic grade: Moderately differentiated. Tumor extent: Not specified. Lymph nodes: 0/10 positive for metastasis (Axillary 0/10). Extracapsular invasion of the lymph nodes: Not specified. Margins: Uninvolved. "". Nottingham Histologic Score. Tubule formation: Not specified. Nuclear pleomorphism: Not specified. Mitotic count (25x): Not specified. Mitotic count (40x): Not specified. Total Nottingham Score: Score cannot be determined. Evidence of neo-adjuvant treatment: Not specified. Additional pathologic findings: Not specified. Comments: None. Laterality: Right, upper outer quadrant.",BRCA,0,"The report states that the tumor size is 2.3 x 0 x 2.5 cm, which falls in the T2 category of being more than 2 cm but not more than 5 cm in size. The T stage is determined by the size of the tumor, and in this case, the size is 2.5 cm, making it a T2 tumor.",T2,4.0
1119,TCGA-D8-A1JC.B4DB830F-BFA4-47F5-94C7-D95984315866,1,"page 1 / 1. copy No. Examination: Histopathological examination. Cost of diagnostic procedure. Gender: F. Material: 1. Multiple organ resection - left breast and axillary tissue. Expected time of examination: up to 8 working days. Clinical diagnosis: Status after intraoperative examination - ca invasivum. Macroscopic description: Left breast sized 21 x 10 x 5 cm removed along with axillary tissues sized 12 x 7 x 15 cm and a 19 x 10 cm skin flap. Weight 820 g. Tumour site sized 11 x 7 x 3 cm on the boundary of outer quadrants, 2 cm from the upper boundary, 0.5 cm from the base and 1. cm from the skin. A. post-operative scar visible in the outer quadrant skin with a seam of 7 cm. Metastatic lymph nodes of 2.5 cm. Microscopic description: Invasio carcinomatosa vasorum. Infiltratio carcinomatosa mamillae. In the tumour site, singular foci of carcinoma ductale invasivum and lesions of the type mastopathia fibrosa et cystica,. hyperplasia ductalis simplex (UDH). AXILLARY LYMPH NODES. Metastases carcinomatosae in lymphonodis No IV/XI. Infiltratio capsulae lymphonodorum. Histpathological diagnosis: Carcinoma ductale partim micropapillare invasivum mammae sinistrae. Invasive ductal carcinoma partially micropapillary of the. left breast. Metastases carcinomatosae in lymphonodis axillae (No IV/XI) (NHG2, pT2, pN2a). Cancer metastases in axillary lymph nodes (No. IV/XI). Invasio carcinoma vasorum. Vascular invasion.",BRCA,2,"The tumor size is 11 x 7 x 3 cm, which is more than 2 cm but not more than 5 cm in its greatest dimension (11 cm). This corresponds to a T2 tumor according to the provided rules.",T2,5.0
1263,TCGA-E2-A56Z.83AAF7BF-131D-4044-AD3B-670B838A23D6,1,"METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Immunohistochemistry was performed using the mouse anti-human ER (ER 1D5, 1:100) and PR (PGR. 136, 1:100) provided by. following the manufacturer S instructions. This. assay was not modified. Interpretation of the ER/PR immunohistochemical stain is guided by published. results in the medical literature, information provided by the reagent manufacturer and by internal. review of staining performance. SYNOPTIC REPORT - BREAST HER-2 RESULTS. Specimen: Breast Core Needle Biopsy. Block Number: Interpretation: EQUIVOCAL. Intensity: 2+. % Tumor Staining: 10%. Fish Ordered: METHODOLOGY: Tissue was fixed in 10% neutral buffered formalin for no less than 8 and no longer than 24 hours. Her2 analysis was performed using the FDA approved. HercepTest (TM) test kit. using rabbit anti-human HER2. This assay was not modified. External kit-slides. provided by the manufacturer (cell lines with high, low and negative HER2 protein expression) and in-. house known HER2 amplified control tissue were evaluated along with the test tissue. Adequate, well. preserved, clear-cut invasive carcinoma was identified for HER2 evaluation. Interpretation of the HER2. immunohistochemical stain is guided by published results in the medical literature, information provided. by the reagent manufacturer and by internal review of staining performance. This assay has been validated according to the. joint recommendations and guidelines from. ASCO and CAP and from the NCCN HER2 testing in Breast Cancer Task Force. The. Pathology Department takes full responsibility for this test's performance. FISH/ISH ANALYSIS REPORT 3. Specimens Involved. Specimens: B: RIGHT BREAST SUBAREOLAR CORE BIOPSY. HER2/NEU RESULTS. ANALYTICAL INTERPRETATION OF RESULTS. INDETERMINATE (EQUIVOCAL) FOR HER-2 AMPLIFICATION. Clinical interpretation of the results. A majority of tumors cells displayed 2 to CEP17 signals and 4 to 5 HER-2 signals, with a HER-2/CEP. 17 Ratio of 2. A HER-2/CEP 17 Ratio of >2.2 is generally considered amplification, while a ratio of 1.8. to <2.2 is generally considered indeterminate. This specimen is a biopsy and recommendation is to. repeat HER2 FISH test on resection specimen. Probes identification. .SI Her-2/neu 17q11.2-12, spectrumorange. CEP 17, 17 p11.1-q11.1 alpha satellite DNA, spectrumgreen. Image analysis method - Manual. Results interpreted. Number of invasive tumor cells counted. 100. Number of observers. 1. Number of Her2 signals/nucleus. 4.0. Number of CEP 17 signals/nucleus. 2.0. Her2/CEP 17 ratio. 2.0. TEST CHARACTERISTICS: PathVysion HER-2 DNA Probe Kit is FDA approved for selection of. patients for whom Herceptin therapy is being considered. These tests were performed in the Pathology. Core Facility, Department of Pathology,. under the direction of Dr.. The. results of these studies should always be interpreted in the context of the clinical, morphological, and. immunophenotypic diagnosis. The. PathVysion Kit is not intended for use to screen for or diagnose breast cancer. It is intended. to be used as an adjunct to other prognostic factors currently used to predict disease-free and overall. survival in stage II, node-positive breast cancer patients. In making decisions regarding adjuvant CAF. treatment, all other available clinical information should also be taken into consideration, such as tumor. size, number of involved lymph nodes, and steroid receptor status. No treatment decision for stage II,. node-positive breast cancer patients should be based on HER-2/neu gene amplification status alone. Specimen information. Block number used. Comment: Controls: The FISH study was performed with appropriately stained positive and negative controls. SPECIMEN(S): A. SLN #1 RIGHT AXILLA. B. LEFT BREAST TISSUE BIOPSY WITH NEEDLE LOCALIZATION. C. RIGHT BREAST TISSUE BIOPSY WITH NEEDLE LOCALIZATION. D. ADDITIONAL MEDIAL SUPERIOR MARGIN RIGHT BREAST. E. RIGHT AXILLARY CONTENTS. CLINICAL HISTORY: None Given. PRE-OPERATIVE DIAGNOSIS: Right breast cancer- left breast atypia. INTRAOPERATIVE CONSULTATION: TPA: SLN #1 right axilla- Positive for carcinoma. Diagnosis called to Dr. at by Dr. DIAGNOSIS: A. LYMPH NODE, SENTINEL #1, RIGHT AXILLA, EXCISION: - METASTATIC CARCINOMA TO ONE OF ONE LYMPH NODE (1/1),. MEASURING 0.3-CM WITH NO EXTRANODAL EXTENSION. B. BREAST, LEFT, WIDE LOCAL EXCISION: - FOCAL FIBROADENOMATOID CHANGES WITH COARSE. CALCIFICATIONS. - BIOPSY SITE CHANGES WITH FIBROSIS, GRANULATION TISSUE,. FOREIGN BODY GIANT CELL REACTION AND FAT NECROSIS, NO. TUMOR SEEN. C. BREAST, RIGHT, WIDE LOCAL EXCISION: - INVASIVE DUCTAL CARCINOMA WITH PAPILLARY AND FOCAL. MUCINOUS FEATURES, SBR GRADE 2, MEASURING 3-CM. - HIGH NUCLEAR GRADE, DUCTAL CARCINOMA IN SITU, SOLID,. MICROPAPILLARY, PAPILLARY AND CRIBRIFORM TYPES WITH. CENTRAL NECROSIS AND MICROCALCIFICATIONS. - SURGICAL RESECTION MARGINS NEGATIVE FOR TUMOR. - BIOPSY SITE CHANGES WITH FIBROSIS, GRANULATION TISSUE,. FOREIGN BODY GIANT CELL REACTION AND FAT NECROSIS. - SEE SYNOPTIC REPORT AND SEE NOTE. D. BREAST, RIGHT, ADDITIONAL MEDIAL SUPERIOR MARGIN, EXCISION: - BREAST TISSUE NO TUMOR SEEN. E. LYMPH NODES, RIGHT, AXILLARY DISSECTION: - FIFTEEN LYMPH NODES, NEGATIVE FOR METASTASES (0/15). NOTE: Invasive ductal carcinoma is identified in 5 consecutive slices from lateral to. medial, measuring about 3.0 CM. HER-2/neu test by FISH is ordered, since the core needle biopsy results were equivocal. SUMMARY OF IMMUNOHISTOCHEMISTRYISPECIAL STAINS. Material: Block A1. Population: Lymph Node. Stain/Marker: Comment: CYTOKERATIN AE1/3. Positive. CYTOKERATIN 7. Negative. S-100. Negative. ESTROGEN RECEPTOR. Positive. Material: Block C7. Population: Tumor Cells. Stain/Marker: Comment: CYTOKERATIN AE1/3. Positive. CYTOKERATIN 7. Negative. S-100. Negative. ESTROGEN RECEPTOR. Positive. Material: Block C12. Population: Tumor Cells. Stain/Marker: Comment: P63. Negative. CALP. Negative. SMOOTH MUSCLE. Negative. MYOSIN. The interpretation of the above immunohistochemistry stain or stains is guided by published results in the medical literature, provided. package information from the manufacturer and by internal review of staining performance and assay validation within the. Immunohistochemistry Laboratory of the. The use of one or more reagents in the above tests is. regulated as an analyte specific reagent (ASR). These tests were developed and their performance characteristic determined by the. Department of Pathology Laboratory at. `hey have not been cleared or approved by the U.S. Food and. Drug Administration. The FDA has determined that such clearance or approval is not necessary. Special stains and/or immunohistochemical stains were performed with appropriately stained positive and/or negative. controls. SYNOPTIC REPORT - BREAST. Specimens Involved. Specimens: A: SLN #1 RIGHT AXILLA. C: RIGHT BREAST TISSUE BIOPSY WITH NEEDLE LOCALIZATION. D: ADDITIONAL MEDIAL SUPERIOR MARGIN RIGHT BREAST. E: RIGHT AXILLARY CONTENTS. Specimen Type: Excision. Needle Localization: Laterality: Right. Invasive Tumor: Present. Multifocality: No. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 3cm. Margins: Negative. Distance from closest margin: 0.4cm. anterior. Tubular Score: 2. Nuclear Grade: 3. Mitotic Score: 3. Modified Scarff Bloom Richardson Grade: 2. Necrosis: Absent. Vascular/Lymphatic Invasion: None identified. Lobular neoplasia: None. Lymph nodes: Sentinel lymph node. Axillary dissection. Lymph node status: Positive 1 / 16. Micrometastases: DCIS present. Margins uninvolved by DCIS. DCIS Quantity: Estimate 10%. DCIS Type: Cribriform. Micropapillary. Papillary. DCIS Location: Associated with invasive tumor. Nuclear grade: High. Necrosis: Present. Location of CA++: DCIS. ER/PR/HER2 Results. ER: Positive. PR: Positive. HER2: Pending by FISH. Performed on Case: ER/PR. on case. HER2 by FISH pending on the current case. Pathological staging (pTN): pT 2 N la. Pathological staging is based on the AJCC Cancer Staging Manual, 7th Edition. GROSS DESCRIPTION: A. SLN #1 RIGHT AXILLA. Received fresh labeled with the patient's identification and 'SLN #1 right axilla' is a tan. pink lymph node 1.7 X 0.9 X 0.7cm. The specimen is serially sectioned. A touch prep is. taken. Toto A1. B. LEFT BREAST TISSUE BIOPSY WITH NEEDLE LOCALIZATION. Received in formalin labeled with the patient's identification and 'left breast tissue. biopsy with needle localization' are two oriented, previously inked lumpectomy. specimens 59g and 53g each - when placed back together by the surgeon, measuring 11.5. x 8 x 4.5cm. Ink code- anterior-yellow, posterior-black, superior-blue, inferior-orange,. medial-green, lateral-red. Specimen is serially sectioned in to 15 slices revealing a 0.6 x. 0.5 x 0.5cm previous biopsy site with surrounding necrosis, at the anterior margin in. slices 4-5-6. The specimen is radiographed and areas of concern are marked by the. radiologist. A biopsy clip is identified in slice 5. Representatively submitted: B1-B2: medial margin slice 1. B3: anterior margin slice 2. B4: anterior margin slice 3. B5: bx site with anterior margin slice 4. B6: inferior margin slice 4. B7: bx site with anterior margin and clip ID slice 5. B8: superior margin slice 5. B9: posterior margin slice 5. B10: inferior margin slice 5. B11: bx site with anterior margin slice 6. B12: superior-posterior margin marked by the radiologist slice 14. B13-B14: inferior margin slice 14. B15: lateral margin marked by the radiologist slice 15. C. RIGHT BREAST TISSUE BIOPSY WITH NEEDLE LOCALIZATION. Received in formalin labeled with the patient's identification and 'right breast tissue. biopsy with needle localization' is an oriented, previously inked 201g, 15.2 x 11 x 3.4cm. needle localized lumpectomy with two radiographs. Ink code- anterior-yellow, posterior-. black, superior-blue, inferior-orange, medial-green, lateral-red. Specimen is serially. sectioned in to 11 slices revealing a tan white gelatinous lobulated mass 5.3 x 4 x 2.8cm,. 0. 1cm from the closest anterior and posterior margins in slices 2-3-4-5-6-7 and 8. A. portion of the specimen is submitted for tissue procurement. Representatively submitted: C1: lateral margin slice 1. C2: mass with anterior margin slice 2. C3: mass with anterior margin slice 3. C4-C5: mass with anterior margin slice 4. C6-C8: mass with anterior margin slice 5. C9: superior margin slice 5. C10-C11: mass with posterior margin slice 6. C12: mass with posterior margin slice 7. C13: anterior - inferior margins slice 7. C14: mass slice 8. C15: inferior margin slice 9. C16: posterior margin slice 10. C17: medial margin slice 11. D. ADDITIONAL MEDIAL SUPERIOR MARGIN RIGHT BREAST. Received in formalin labeled with the patient's identification and ""additional medial. superior margin right breast' is an oriented 37g, 7 x 7 x 3cm fibrofatty tissue. Final. margin inked blue. Serial sectioning reveals unremarkable parenchyma. Representatively. submitted in D1-D6. E. RIGHT AXILLARY CONTENTS. Received in formalin labeled with the patient's identification and ""right axillary contents'. are multiple tan pink fragments of fibrofatty tissue aggregating to 15 x 8 x 3.5cm. Dissection reveals sixteen lymph nodes ranging from 3.5 x 2.4 x 1.6cm to 0.2 x 0.2 x. 0.2cm. E1: five lymph nodes. E2: five lymph nodes. E3: two lymph nodes. E4: one lymph node. E5-E6: one lymph node. E7-E8: one lymph node. E9-E10: one lymph node. ADDENDUM: FISH/ISH ANALYSIS REPORT 3. Specimens Involved. Specimens: C: RIGHT BREAST TISSUE BIOPSY WITH NEEDLE LOCALIZATION. HER2/NEU RESULTS. ANALYTICAL INTERPRETATION OF RESULTS. HER-2 NOT AMPLIFIED. Clinical interpretation of the results. A majority of tumors cells displayed moderate polysomy 17 with 2 to 3 chromosome 17. centromere signals and 2 to 4 HER2 signals, with a HER2/CEP 17 Ratio 1.5, consistent with. no amplification of the HER2/neu gene. Probes identification. LSI Her-2/neu 17q11.2-12, spectrumorange. CEP 17, 17 p11.1-q11.1 alpha satellite DNA, spectrumgreen. Image analysis method - Manual. Results interpreted. ISCN. nuc ish: (CEP17x2),(HER2x3)[200]. Number of invasive tumor cells counted. 200. Number of observers. 1. Number of Her2 signals/nucleus. 3.2. Number of CEP 17 signals/nucleus. 2.2. Her2/CEP 17 ratio. 1.5. TEST CHARACTERISTICS: HER-2 DNA Probe Kit is FDA approved for. selection of patients for whom Herceptin therapy is being considered. These tests were. performed in the Pathology Core Facility, Department of Pathology,. under the direction of Dr.. The results of these studies should always be. interpreted in the context of the clinical, morphological, and immunophenotypic diagnosis. The. Kit is not intended for use to screen for or diagnose breast cancer. It. is intended to be used as an adjunct to other prognostic factors currently used to predict. disease-free and overall survival in stage II, node-positive breast cancer patients. In. making decisions regarding adjuvant CAF treatment, all other available clinical. information should also be taken into consideration, such as tumor size, number of. involved lymph nodes, and steroid receptor status. No treatment decision for stage II,. node-positive breast cancer patients should be based on HER-2/neu gene amplification. status alone. Specimen information. RPCI surgical pathology/cytology case number. Source of case. RPCI. Block number used C7. Specimen site. Breast. Female breast right. Specimen type. Complete excision (less total mastectomy). Specimen fixative type. Formalin. Duration of fixation (hrs). 6 48 hrs. Comment: Controls: The FISH study was performed with appropriately stained positive and negative. controls. ADDENDUM: ONCOTYPE DX BREAST CANCER ASSAY. RESULTS: Recurrence Score: 27. CLINICAL EXPERIENCE: Patients with a recurrence score of: 27 in the clinical validation. study had an average rate of Distant Recurrence at 10 years of 18%. ER Score: 12 Positive. PR Score: 6.7 Positive. Her2 Score: 9.1 Negative. Interpretation: ER. Negative < 6.5 Positive >= 6.5. PR. Negative < 5.5 Positive >= 5.5. Her2 Negative <10.7 Positive >= 11.5 Equivocal = 10.7 - 11.4. See separate. report for further information. left breast bx. SPECIMENS: A. LEFT BREAST CENTRAL CORE BIOPSY. B. RIGHT BREAST SUBAREOLAR CORE BIOPSY. SPECIMEN(S): A. LEFT BREAST CENTRAL CORE BIOPSY. B. RIGHT BREAST SUBAREOLAR CORE BIOPSY. DIAGNOSIS: A. BREAST, LEFT, CENTRAL, BIOPSY: - MINUTE FRAGMENTS OF ATYPICAL CELLS WITH NECROSIS. - STROMAL CALCIFICATIONS, SEE NOTE. NOTE: Scattered minute fragments of crushed cells with necrosis are identified. They may represent. contents of DCIS. Multiple levels are examined. Excisional biopsy is recommended. B. BREAST, RIGHT, SUBAREOLAR, BIOPSY: - INVASIVE DUCTAL CARCINOMA, SBR GRADE 2, SEE NOTE. NOTE: Maximum invasive tumor size measures 0.8-cm. This measurement may not reflect the actual. size of the tumor. Breast biomarkers are ordered. GROSS DESCRIPTION: A. LEFT BREAST CENTRAL CORE BIOPSY. Received in formalin labeled with the patient's identification and 'left breast central core biopsy' are. multiple tan vellow cores of tissue ranging from 4.3 x 0.2cm to 0.5 x 0.2cm. Toto A1-A2. Time placed in. formalin-. B. RIGHT BREAST SUBAREOLAR CORE BIOPSY. Received in formalin labeled with the patient's identification and 'right breast subareolar core biopsy' are. four tan yellow cores of tissue ranging from 1.1 x 0.1cm to 0.5 x 0.1cm. Toto B1. Time placed in. formalin-. CLINICAL HISTORY: A) Suspicious calcification in central left breast. B) New mass - highly suspicious for cancer. PRE-OPERATIVE DIAGNOSIS: A) Rule out DCIS. ADDENDUM: SYNOPTIC REPORT - BREAST, ER/PR RESULTS. Specimen: Breast Core Needle Biopsy. Block Number: ER: Positive. Allred Score: 8 = Proportion Score 5 + Intensity Score 3. PR: Positive Allred Score: 5 = Proportion Score 2 + Intensity Score 3. COMMENT: The Allred score for estrogen and progesterone receptors is calculated by adding the sum of the. proportion score (0 = no staining, 1 = <1% of cells staining, 2 = 1 - 10% of cells staining, 3 = 11-30% of. cells staining, 4 = 31-60% of cells staining, 5 = >60% of cells staining) to the intensity score (1 = weak. intensity of staining, 2 = intermediate intensity of staining, 3 = strong intensity of staining), with a scoring. range from 0 to 8. ER/PR positive is defined as an Allred score of >2 and ER/PR negative is defined as an Allred score. of less than or equal to 2.",BRCA,1,"The tumor size is reported as 3 cm, which falls within the T2 category of 'more than 2 cm but not more than 5 cm in size'. The T stage is determined solely by the size of the tumor and is not affected by the lymph node status or tumor grade.",T2,6.0
1257,TCGA-E2-A1LK.6CC4E6EF-6664-448E-933E-FFA9117C7ABF,3,"SPECIMENS: A. LEFT MODIFIED RADICAL MASTECTOMY. B. LEFT AXILLARY CONTENTS LEVELS 1 AND 2. SPECIMEN(S): A. LEFT MODIFIED RADICAL MASTECTOMY. B. LEFT AXILLARY CONTENTS LEVELS 1 AND 2. INTRAOPERATIVE CONSULTATION DIAGNOSIS: Gross Exam A Left breast, modified radical mastectomy: Tumor is grossly 0.1 cm for posterior margin. and >0.5 cm from other margins. By Dr., called to Dr. at. GROSS DESCRIPTION: A. LEFT MODIFIED RADICAL MASTECTOMY. Received fresh labeled with the patient name designated ""left modified radical mastectomy"", is a. resected mastectomy specimen weighing 203 grams and measuring 19.6 x 7.5 x 5.8 cm. Specimen is. received with orientation, a suture indicating the axillary tail. The ellipse of beige-tan skin measures. 15.8 x 7.2 cm. The light brown areola measures 2.5 cm in diameter. The everted nipple measures 1.3. cm in diameter. The surface of the skin shows two firm masses, the larger measuring 2.5 x 2, the. smaller measuring 0.6 x 0.6 cm. A large mass is palpated beneath the two lesions. The deep posterior. margin is inked black, the anterior is inked orange. The specimen is serially sectioned from lateral to. medial. Cut section shows a beige-tan firm, slightly necrotic mass which demonstrates a thick amber. colored mucoid fluid. The mass lies just beneath the deep margin at a distance of 0.1 cm. The mass. occupies the upper outer quadrant into the axillary tail. The mass measures 6.8 x 6.5 x 3.5 cm. The. remainder of the specimen shows dark yellow lobulated adipose tissue with focal areas of white firm,. fibrous parenchyma. A portion of the specimen is submitted for tissue procurement. Gross. photographs are taken. Representative sections are submitted as follows: A1-A2: sections of lesion and closest margin, posterior, and skin. A3-A4: one full thickness section from skin to deep margin with lesion. A5-A11: sections of lesion from upper-outer quadrant through mid portion. A12-A13: sections of lower-outer quadrant. A14-A15: representative sections lower-inner quadrant. A16-A17: representative sections upper-inner quadrant. A18-A19: sections of nipple. A20-A24: axillary lymph nodes, 2 sections from each. B. LEFT AXILLARY CONTENTS LEVELS 1&2. Received fresh are multiple tan-pink fragments of fibrofatty tissue aggregating to 6.0 x 3.0 x 2.0 cm. Dissection reveals 13 possible lymph nodes ranging from 0.1 x 0.1 x 0.1 cm to 3.5 x 2.5 x 2.0 cm. Section code: B1: Three possible lymph nodes. B2: Four possible lymph nodes. B3: Two possible lymph nodes. B4: Two possible lymph nodes. B5: One lymph node serially sectioned. B6-B10: Largest lymph node serially sectioned. DIAGNOSIS: A. BREAST, LEFT, MODIFIED RADICAL MASTECTOMY: MULTIFOCAL, INVASIVE, DUCTAL CARCINOMA, SBR GRADE 3 WITH. NECROSIS, LARGEST FOCUS MEASURES 6.8-CM, INVOLVING LATERAL. HALF OF THE BREAST WITH EXTENSION TO SUPERFICIAL DERMIS. - SURGICAL RESECTION MARGINS ARE NEGATIVE FOR CARCINOMA. - LYMPHOVASCULAR AND PERINEURAL INVASIONS IDENTIFIED. - METASTATIC CARCINOMA TO TWO OF THREE LYMPH NODES (2/3), WITH. EXTRANODAL EXTENSION, LARGEST MEASURING 2.8-CM. - SEE SYNOPTIC REPORT. B. LYMPH NODES, LEFT AXILLARY CONTENTS, LEVELS 1 AND 2, RESECTION: - METASTATIC CARCINOMA TO NINE OF TWELVE LYMPH NODES (9/12),. WITH EXTRANODAL EXTENSION, LARGEST MEASURING 3.5-CM. SYNOPTIC REPORT - BREAST. Specimen Type: Mastectomy. Needle Localization: No. Laterality: Left. Invasive tumor: Present. Multifocality: Yes. WHO CLASSIFICATION. Invasive ductal carcinoma, NOS 8500/3. Tumor size: 6.8cm. Tumor site: Upper outer quadrant. Lower outer quadrant. Margins: Negative. Distance from closest margin: 0.4cm. deep. Tubular score: 3. Nuclear grade: 3. Mitotic score:3. Modified Scarff Bloom Richardson Grade: 3. Necrosis: Present. Vascular/Lymphatic Invasion: Present. Extent: focal. Lobular neoplasia: None. Lymph nodes: Axillary dissection. Lymph node status: Positive 11 / 15 Extranodal extension. Non-neoplastic areas: fibroadenoma. DCIS not present. ER/PR/HER2 Results. Performed on Case: ER: Negative. PR: Negative. HER2: Negative by FISH. Pathological staging (pTN): pT 3 N 3a. CLINICAL HISTORY: year old female with large left breast IDC/ulcerating - now for modified radical mastectomy (left). PRE-OPERATIVE DIAGNOSIS: Left breast carcinoma. Microscopic/Diagnostic Dictation: Pathologist,. Final Review: Pathologist. Microscopic/Diagnostic Dictation: Pathologist,. Final Review:. Pathologist,. Final: Pathologist,.",BRCA,3,"The tumor size is reported as 6.8 cm, which falls in the T3 category of 'Tumors more than 5 cm in size'. The T stage is determined solely by the size of the tumor and is not affected by the lymph node status or the differentiation of the tumor cells.",T3,7.0
